Vertex Pharma (VRTX) Tops Q1 EPS by 4c; Reiterates Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Vertex Reports First Quarter 2022 Financial Results
May 5, 2022 4:01 PM EDTProduct revenues of $2.10 billion, a 22% increase compared to Q1 2021
Company reiterates full year 2022 product revenue guidance of $8.4 to $8.6 billion
Mid- and late-stage clinical pipeline now spans 6 disease areas
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results... More



